AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02518126 — intervention group
Intervention type: OTHER
Intervention: blood sample and tissue sample
Description: After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos
Study NCT03585413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient-probiotic-combination
Description: Specific combined micronutrient-probiotic-supplement with different vitamins, minerals, phytochemicals and bioactive substances, and a mixture of 10 different probiotic bacteria.
Study NCT03585413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Micronutrient-placebo-combination
Description: micronutrient (capsule)-placebo (powder)-supplement
Study NCT03939091 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasonography
Description: Renal Ultrasonography
Study NCT04049786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digestive biopsy
Description: All patients with indication for RYGB bariatric surgery undergo to endoscopy before and after the surgery as standard protocol. Digestive biopsy are being performed in obese and post-RYGB patients for transcriptomic analysis
Study NCT02747199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYNERGY stent
Study NCT02747199 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BVS ABSORB scaffold
Study NCT04161495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efanesoctocog alfa (BIVV001)
Description: Pharmaceutical form: solution for injection Route of administration: IV injection
Study NCT02319577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vinorelbine
Description: Anti-neoplastic drug (PO chemotherapeutical agent, vinka alkaloid)
Study NCT02319577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: EGFR tyrosine kinase inhibitor
Study NCT02319577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: EGFR tyrosine kinase inhibitor
Study NCT04433546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemziviptadil (PB1046)
Description: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
Study NCT04433546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low Dose (10 mg) Control
Description: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection (10 mg diluted in sodium chloride to match active drug volume)
Study NCT03182452 — intervention group
Intervention type: OTHER
Intervention: Alarm Advisor
Description: Providing advice on alarm limits as part of routine medical care
Study NCT04219397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication take back
Description: Patients will be provided with formal education about medication take back programs for left-over prescription medications. They will be provided with directions to the closest medication take back facility to their home, and directions to the closet medication take back facility near their post-operative clinic site, and instructed to dispose of any left-over oxycodone medication (at completion of analgesic therapy) through participating in medication take back.
Study NCT04219397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication home disposal
Description: Patients and their families will be provided with formal education about how to use the medication home disposal kit: Dispose Rx, provided with a Dispose Rx home disposal kit, and instructed to dispose of any left-over oxycodone prescription medications with this kit following completion of analgesic therapy.
Study NCT00125502 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV gB vaccine
Description: CMV gB is combined with a novel adjuvant, MF59, a proprietary oil-in-water emulsion, administered at 0, 1, and 6 months.
Study NCT00125502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59 adjuvant
Description: Oil-in-water emulsion
Study NCT00125502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution
Study NCT04188691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）
Description: Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
Study NCT04188691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）
Description: Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
Study NCT04188691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）
Description: Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）administered intramuscularly according to a 0, 28，（56）day vaccination schedule
Study NCT04188691 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline administered intramuscularly according to a 0, 28 ，（56）day vaccination schedule
Study NCT04188691 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Aluminum adjuvant
Description: Aluminum adjuvant administered intramuscularly according to a 0, 28，（56） day vaccination schedule
Study NCT01757808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.
Study NCT01757808 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo at a dose of 500mg for one month followed by a dose of 1000mg.
Study NCT03854045 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telepsychiatry
Description: Receive telepsychiatry with clinician obtaining initial data and presenting it to the psychiatrist
Study NCT03854045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telepsychiatry
Description: Receive telepsychiatry with clinician obtaining initial data and presenting it to the psychiatrist
Study NCT00515632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balaglitazone
Description: One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
Study NCT00515632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balaglitazone
Description: One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
Study NCT00515632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Balaglitazone
Description: One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
Study NCT04578782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.
Study NCT03562247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care of IPF
Description: standard of care given to patients with IPF
Study NCT03562247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care of IPF
Description: standard of care given to patients with IPF
Study NCT03562247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telenursing
Description: scheduled phone calls with the patient and care giver
Study NCT03562247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telenursing and Remote Monitoring
Description: scheduled phone calls and home monitoring of physiologic parameters
Study NCT03302351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
Study NCT03302351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: 31 patients will receive intravenous ketamine 0.4 mg/kg.
Study NCT03302351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmetedomidine+Ketamine
Description: 33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg + low dose ketamine 0.25mg/kg.
Study NCT02798965 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: serodiagnosis
Study NCT02798965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serodiagnosis
Study NCT04580329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation (NMES) in addition to routine hospital care
Description: Patients in the NMES group will receive NMES sessions as the electrodes will be placed around the bilateral femoral quadriceps muscles and at the site of renal arteries.~NMES(>100 Hz, 50-80 μ sec) will be performed for 55 min including 5 minutes for warm up and 5 minutes for recovery .~The intensity of electrical stimulation will be adjusted to suit the comfort level of each individual patient without producing discomfort or pain.
Study NCT04580329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine hospital care without NMES
Description: routine hospital care include all the routine intervention done for post partum women with AKI including fluid resuscitation, diuretics, hemodialysis
Study NCT04049786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 25mg
Description: Single-dose of carvedilol 25 mg are being administrated orally.
Study NCT03815786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: 2-months oral administration of the symbiotic supplement (2 bags/day) + 1 month washout
Study NCT03815786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Symbiotic
Description: 2-months oral administration of the symbiotic supplement (2 bags/day) + 1 month washout
Study NCT03815786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2-months oral administration of the placebo (2 bags/day) + 1 month washout
Study NCT03815786 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: 2-months oral administration of the placebo (2 bags/day) + 1 month washout
Study NCT00304525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAF265
Description: A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.
Study NCT02112838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib 150 mg
Description: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Study NCT02112838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fostamatinib 100 mg
Description: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Study NCT02112838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily by mouth, over the course of 24 weeks
Study NCT05314920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive-behavioral therapy (TD-CBT)
Description: Transdiagnostic cognitive-behavioral therapy (TD-CBT)
Study NCT05314920 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bernstein and Borkovec progressive muscle relaxation (PMR)
Description: Bernstein and Borkovec progressive muscle relaxation (PMR)
Study NCT00557648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for children
Description: CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
Study NCT00557648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for children plus parent training
Description: CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
Study NCT00547820 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00547820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urinary sensor
Study NCT04308343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Drugs to treat undisturbed ectopic pregnancies
Study NCT04308343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Drugs to treat undisturbed ectopic pregnancies
Study NCT04308343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrotide
Description: Drugs to treat undisturbed ectopic pregnancies
Study NCT00513643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: 6, 12, 24 U s.c.
Study NCT00513643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human regular insulin
Description: 6, 12 and 24 IU sc
Study NCT01296347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
Study NCT03881618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture+auricular pressure,
Description: electroacupuncture+auricular pressure for 20 minutes
Study NCT03881618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electroacupuncture+auricular pressure,
Description: electroacupuncture+auricular pressure for 20 minutes
Study NCT03824782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy Mask
Description: A standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided.
Study NCT02197767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 1000 mg infusion
Study NCT03038230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-117 bispecific antibody
Description: MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3
Study NCT00413972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe with simvastatin
Description: Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
Study NCT00413972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe with Simvastatin
Description: Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
Study NCT00413972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe with Simvastatin
Description: Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks
Study NCT00413972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for a total of eight weeks
Study NCT03197779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-962212
Description: Intravenous Infusion administration over 2 hours or 5 days
Study NCT03197779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral administration
Study NCT03197779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Oral administration
Study NCT03197779 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT04412291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra Prefilled Syringe
Description: A total dose of 400mg per day (divided in 4 doses of 100 mg iv every 6 hours) for 7 days.
Study NCT04412291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab Prefilled Syringe
Description: 8mg/kg for a single infusion iv up to max 800 mg. If no clinical response is obtained, another dose of 8mg/kg may be administered after earliest 2 days after inclusion with the following condition: The clinical symptoms are worsened (as assessed by decreasing PaO2/FiO2 and/or need of increased ventilatory support such as NIV, HFNC or mechanical ventilation).
Study NCT04412291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care treatment
Description: SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)
Study NCT04320394 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: QuantiFERON Monitor®
Description: The test will be realised to evaluate sepsis induced immunosuppression on patient with septic shock
Study NCT05998538 — intervention group
Intervention type: PROCEDURE
Intervention: Knee Replacement
Description: Total vs Partial Knee Replacement
Study NCT01502020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imiquimod cream, 3.75%
Description: Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
Study NCT01502020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
Study NCT01502020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod cream, 3.75%
Description: Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
Study NCT03329560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral fecal microbiota transplantation
Description: All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
Study NCT00348855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular drugs strategies
Description: Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.
Study NCT00348855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compliance
Description: Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.
Study NCT00348855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.
Study NCT00348855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop Smoking
Description: Minimal intervention
Study NCT00348855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.
Study NCT00348855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feed Back
Description: Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
Study NCT02388685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home exercise therapy
Study NCT01372865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Study NCT04049786 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial blood sampling for PK analysis
Description: Serial blood samples are being collected at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after drug administration for PK evaluation .
Study NCT01372865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate
Study NCT02216474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study NCT02216474 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Study NCT00585195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02341066
Description: Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).